Technical Analysis for GLPGF - Galapagos Genomics Ord

Grade Last Price % Change Price Change
D 58.05 -3.68% -2.2168
GLPGF closed down 3.68 percent on Tuesday, May 17, 2022, on 3 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
MACD Bullish Centerline Cross Bullish -3.68%
Narrow Range Bar Range Contraction -3.68%
Overbought Stochastic Strength -3.68%
Gapped Down Weakness -3.68%
Crossed Above 50 DMA Bullish -9.30%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Galapagos Genomics Ord Description

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.


Classification

Keywords: Medicine Biotechnology Medical Specialties Clinical Medicine Arthritis Rheumatoid Arthritis Molecules Taxi Ulcer Osteoarthritis Dermatitis Stage Biotechnology Atopic Dermatitis Cyst Fibrosis Ilg Crohn's Disease Ulcerative Colitis Colitis Evotec Idiopathic Pulmonary Fibrosis Cystic Fibrosis Treatment Of Osteoarthritis Gilead Sciences Morphosys Pulmonary Fibrosis

Is GLPGF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 268.651
52 Week Low 48.55
Average Volume 7,522
200-Day Moving Average 115.5409
50-Day Moving Average 58.1298
20-Day Moving Average 53.3698
10-Day Moving Average 55.7447
Average True Range 2.4191
RSI 53.70
ADX 22.87
+DI 52.2393
-DI 47.0509
Chandelier Exit (Long, 3 ATRs) 56.7427
Chandelier Exit (Short, 3 ATRs) 55.8073
Upper Bollinger Bands 61.0600
Lower Bollinger Band 45.6796
Percent B (%b) 0.8
BandWidth 28.8185
MACD Line 0.3683
MACD Signal Line -1.1011
MACD Histogram 1.4694
Fundamentals Value
Market Cap 3.15 Billion
Num Shares 54.3 Million
EPS -1.69
Price-to-Earnings (P/E) Ratio -34.43
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 58.0500
Resistance 3 (R3) 58.0500 58.0500 58.0500
Resistance 2 (R2) 58.0500 58.0500 58.0500 58.0500
Resistance 1 (R1) 58.0500 58.0500 58.0500 58.0500 58.0500
Pivot Point 58.0500 58.0500 58.0500 58.0500 58.0500
Support 1 (S1) 58.0500 58.0500 58.0500 58.0500 58.0500
Support 2 (S2) 58.0500 58.0500 58.0500 58.0500
Support 3 (S3) 58.0500 58.0500 58.0500
Support 4 (S4) 58.0500